
Potency Assays for MSC Exosomes: Why Particle Counts Fall Short
A vial label that reads "10 billion particles" says how much material is present. It does not say whether that material does anything. In biologics development, the attribute that addresses biological activity is potency, and for mesenchymal stromal cell (MSC)-derived exosomes it remains one of the hardest quality questions to answer. This article explains what a potency assay is, why the field has not settled on one, and what research buyers can reasonably ask a supplier today.
Identity, Quantity, and Potency Are Different Questions
Release testing for an extracellular vesicle (EV) preparation typically addresses several separate attributes. Identity asks whether the material is what it claims to be, usually through particle size and marker proteins. Quantity asks how much is present. Purity and safety testing cover co-isolated contaminants, sterility, endotoxin, and mycoplasma. Potency asks something different: does this lot show a defined, measurable biological activity relevant to its intended use?
A lot can pass identity and quantity testing and still vary in activity, because particle counters measure particles, not function. Our overview of how MSC exosomes are characterized covers the identity and safety side; potency is the layer above it.
Why Particle Count and Protein Are Weak Surrogates
The MISEV2023 guidance from the International Society for Extracellular Vesicles is direct about the limits of common measurements. Where a technique cannot distinguish vesicles from co-isolated material, the result should be reported as a particle concentration, not an EV concentration. Total protein as a stand-in for EV quantity is generally not recommended, since soluble proteins that co-purify with vesicles inflate the number. The guidance also asks investigators to report each assay's limit of detection and to show linearity with dilution series.
On markers, MISEV2023 notes that no generic marker identifies all EVs. It recommends reporting at least one protein from each of three categories: membrane-associated proteins such as the tetraspanins CD9, CD63, and CD81; cytosolic proteins such as TSG101 and ALIX; and common contaminants such as apolipoproteins as a purity control. These establish that vesicles are present and reasonably clean. None of them measures activity.
Why a Standard Potency Assay Does Not Yet Exist
A widely cited position paper by Gimona and colleagues in Cytotherapy lays out the core difficulty. A potency assay should ideally reflect the product's mechanism of action. For MSC-derived small EVs, described there as vesicles of roughly 50 to 200 nm that carry much of the paracrine activity of the parent cells, the mechanism is likely complex, differs by disease context, and is still being worked out.
The authors propose a pragmatic route: identify the EV attribute most relevant to the intended biological activity, then quantify that attribute in an assay capable of meeting regulatory expectations for validation under ICH guidelines. This means potency is defined relative to an intended use. An assay built around immune modulation may say little about activity in a tissue-repair model, and a single universal potency number for "MSC exosomes" is not a realistic expectation.
The same paper stresses that EVs are products of living cells, so donor, culture conditions, and process changes can all shift the result. Manufacturing consistency and potency testing are therefore tied together.
The Clinical Consequence: Doses That Cannot Be Compared
The lack of an agreed potency measure shows up directly in the clinical literature. A 2025 registry analysis in Frontiers in Medicine reviewed MSC-EV trials registered from 2014 to 2024 and called dose-response a critical but underappreciated gap, with doses expressed in non-interchangeable units across studies. An earlier scoping review of registered EV trials in Cytotherapy reached a similar conclusion, calling for more standardized product characterization and quantifiable product quality attributes.
Until dose can be expressed in units of activity, two preparations with identical particle counts cannot be assumed to be equivalent. That is a reason for caution in interpreting any published result, and a reason to hold research material constant within a study.
What Research Buyers Can Reasonably Ask
Because there is no compendial potency assay, the useful questions are about transparency and consistency. Ask how particle concentration was measured and on which instrument. Ask which identity markers were tested and whether a contaminant marker was included. Ask whether the supplier runs any functional assay, what it measures, and whether results are tracked lot to lot. Ask what is held constant in the process: cell source, passage range, culture medium, and isolation method.
A supplier that describes a functional assay honestly, including its limits, is giving more useful information than one that offers an unexplained "potency" figure. Lot-specific results belong on the certificate of analysis; see How to Read a Certificate of Analysis (CoA) for MSC Exosomes.
Where BioRegenEx Stands
There are no FDA-approved exosome products, and potency standards for EV preparations are still being developed by the scientific and regulatory community. BioRegenEx supplies MSC-derived exosomes for research use only. Our material is cGMP-manufactured in an FDA-registered U.S. facility and ethically sourced from human umbilical cord (Wharton's Jelly) MSCs, with lot-specific documentation so that researchers can account for the material they use. More background is available on our exosome research page.
References
- Gimona M, et al. Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy. 2021.
- Welsh JA, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles. 2024.
- Wang Y, et al. Trends in mesenchymal stem cell-derived extracellular vesicles clinical trials 2014–2024: is efficacy optimal in a narrow dose range? Frontiers in Medicine. 2025.
- Registered clinical trials investigating treatment with cell-derived extracellular vesicles: a scoping review. Cytotherapy. 2023.
These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx exosome products are provided for research use only and are not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Any treatment decision is made solely between a patient and a licensed healthcare provider.
